Transparency Market Research in its new report titled, “Aromatase Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the aromatase inhibitor drugs market. The TMR report anticipates that the rise in prevalence of breast cancer across the world will boost the aromatase inhibitor drugs market during the forecast period i.e, 2018-2026.
The report says that according to the Centers for Disease Control and Prevention (CDC), nearly 2,141 men and 236,968 women were diagnosed with breast cancer, and nearly 465 men and 41,211 women succumbed to the disease in the U.S. in 2014. According to the American Cancer Society, breast cancer accounted for 40,610 deaths, and 252,710 new invasive breast cancer and 63,410 non-invasive breast cancer cases were reported in 2017. According to Cancer Research UK, breast cancer accounted for 11,433 deaths in 2014, and 55,122 new cases of invasive breast cancer were registered in the U.K. in 2015. Increase in awareness about cancer drives demand for aromatase inhibitor drugs across the world. Rise in research and development on aromatase inhibitor drugs is attributed to the significant growth of the global aromatase inhibitor drugs market. According to The Pink Initiative, breast cancer accounted for 47,984 female deaths and 187,213 new cases were reported among women in China in 2012.
The global aromatase inhibitor drugs market is segmented based on product, distribution channel, and region. On the basis of product, the market is categorized into letrozole, exemestane, testolactone, and anastrozole. In terms of distribution channel, the global aromatase inhibitor drugs market is classified into retail pharmacies, online pharmacies, and hospital pharmacies. On a geographical standpoint, the global aromatase inhibitor drugs market is split into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held the largest market share owing to increase in health care expenditure and rise in prevalence of breast cancer. Europe held the second largest market share in 2017 due to increase in research and development on aromatase inhibitor drugs in the region. High incidence of breast cancer in developing countries and investment by key players in emerging economies with large patient population are anticipated to drive the market in Asia Pacific. The global aromatase inhibitor drugs market in Middle East & Africa is expected to be driven by rise in prevalence of breast cancer. The market in Latin America is expected to grow at a rapid pace during the forecast period from 2018 to 2026 due to increase in awareness about breast cancer among the people.
Some of the key players operating in the global aromatase inhibitor drugs market are profiled in this report to give a better competitive analysis and these include Novartis AG, Bristol-Myers Squibb and Company, AstraZeneca, and Pfizer, Inc.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]